Only slightly more than one-third of people diagnosed with non-small cell lung cancer (NSCLC) receive personalized treatment based on actionable biomarkers, according to a 2022 study (JCO Precis Oncol 2022;6:e2200246). Participants at an AMCP Nexus 2024 session, in Las Vegas, noted that the consequences of inappropriate treatment can be severe.
OCTOBER 16, 2024
Promise and Hurdles in Personalized Medicine
By Marcus A. Banks